Literature DB >> 16557419

Pancreatic cancer: surgery alone is not sufficient.

L W Traverso1.   

Abstract

For a patient with resected pancreatic cancer at the head of the pancreas, the goal of the medical community in the new millennium is a long-term survival rate exceeding 50% at 5 years. This goal can best be achieved with the following formula: accurate staging by improved imaging that includes laparoscopy for selected patients with locally extensive disease using computed tomography; a balanced resection, not too extensive and not too limited; centralized treatment in high-volume centers, which includes not just the surgeons and hospitals, but also the chemotherapy infusion units; and use of an effective adjuvant or neoadjuvant treatment in which toxicity is associated with efficacy. The ideal outcome for the surgeon is delivery of a patient who has been accurately staged to receive the most appropriate treatment in a timely fashion for an effective chemoradiotherapy protocol. To do this, the surgeon should use objective benchmarks of safe pancreatic resection, which involves resecting only enough, achieving low blood loss, and achieving a minimal length of hospital stay. The outcome is a patient who has optimized his or her gastrointestinal, endocrine, and exocrine functions and is ready for adjuvant treatment 6 weeks after resection. Surgery alone is not sufficient.

Entities:  

Mesh:

Year:  2006        PMID: 16557419     DOI: 10.1007/s00464-006-0052-1

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  14 in total

1.  Hospital volume and surgical mortality in the United States.

Authors:  John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

2.  Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.

Authors:  T A Sohn; C J Yeo; J L Cameron; L Koniaris; S Kaushal; R A Abrams; P K Sauter; J Coleman; R H Hruban; K D Lillemoe
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

3.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

4.  Intraoperative transfusion: is it a real prognostic factor of periampullary cancer following pancreatoduodenectomy?

Authors:  Sang-Jae Park; Sun-Whe Kim; Jin-Young Jang; Kuhn-Uk Lee; Yong-Hyun Park
Journal:  World J Surg       Date:  2002-02-04       Impact factor: 3.352

5.  A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma.

Authors:  Michael B Farnell; Randall K Pearson; Michael G Sarr; Eugene P DiMagno; Lawrence J Burgart; Tamela R Dahl; Nathan Foster; Daniel J Sargent
Journal:  Surgery       Date:  2005-10       Impact factor: 3.982

6.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

7.  Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Vincent J Picozzi; Richard A Kozarek; L William Traverso
Journal:  Am J Surg       Date:  2003-05       Impact factor: 2.565

8.  Useful benchmarks to evaluate outcomes after esophagectomy and pancreaticoduodenectomy.

Authors:  L William Traverso; Hiroyuki Shinchi; Donald E Low
Journal:  Am J Surg       Date:  2004-05       Impact factor: 2.565

9.  The influence of perioperative blood transfusion on survival after esophageal resection for carcinoma.

Authors:  Stephen M Langley; Christos Alexiou; Daniel H Bailey; David F Weeden
Journal:  Ann Thorac Surg       Date:  2002-06       Impact factor: 4.330

10.  Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer.

Authors:  J G Houbiers; A Brand; L M van de Watering; J Hermans; P J Verwey; A B Bijnen; P Pahlplatz; M Eeftinck Schattenkerk; T Wobbes; J E de Vries
Journal:  Lancet       Date:  1994-08-27       Impact factor: 79.321

View more
  16 in total

1.  Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer.

Authors:  Sohei Satoi; Hideyoshi Toyokawa; Hiroaki Yanagimoto; Tomohisa Yamamoto; Minoru Kamata; Chisato Ohe; Noriko Sakaida; Yoshiko Uemura; Hiroaki Kitade; Noboru Tanigawa; Kentaro Inoue; Yoichi Matsui; A-Hon Kwon
Journal:  J Gastrointest Surg       Date:  2011-12-09       Impact factor: 3.452

2.  Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.

Authors:  Olivier Turrini; Joshua A Waters; Thomas Schnelldorfer; Keith D Lillemoe; Constantin T Yiannoutsos; Michael B Farnell; Michael G Sarr; C Max Schmidt
Journal:  HPB (Oxford)       Date:  2010-09       Impact factor: 3.647

3.  Risk-adapted anastomosis for partial pancreaticoduodenectomy reduces the risk of pancreatic fistula: a pilot study.

Authors:  Marco Niedergethmann; Niloufar Dusch; Rizky Widyaningsih; Christel Weiss; Peter Kienle; Stefan Post
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

4.  A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer.

Authors:  Thomas J Howard; Joseph E Krug; Jian Yu; Nick J Zyromski; C Max Schmidt; Lewis E Jacobson; James A Madura; Eric A Wiebke; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

5.  Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy.

Authors:  Takahiro Akahori; Masayuki Sho; Shoichi Kinoshita; Minako Nagai; Satoshi Nishiwada; Toshihiro Tanaka; Tetsuro Tamamoto; Chiho Ohbayashi; Masatoshi Hasegawa; Kimihiko Kichikawa; Yoshiyuki Nakajima
Journal:  World J Surg       Date:  2015-12       Impact factor: 3.352

6.  The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer.

Authors:  Kazuyuki Matsumoto; Toshiaki Ohara; Masayoshi Fujisawa; Akinobu Takaki; Masahiro Takahara; Noriyuki Tanaka; Hironari Kato; Shigeru Horiguchi; Ryuichi Yoshida; Yuzo Umeda; Soichiro Fushimi; Takahito Yagi; Akihiro Matsukawa; Hiroyuki Okada
Journal:  J Gastroenterol       Date:  2019-04-29       Impact factor: 7.527

7.  Prediction of anastomotic leakage after pancreatic head resections by dynamic magnetic resonance imaging (dMRI).

Authors:  Dietmar J Dinter; Niloufar Aramin; Christel Weiss; Christoph Singer; Gerald Weisser; Stefan O Schoenberg; Stefan Post; Marco Niedergethmann
Journal:  J Gastrointest Surg       Date:  2008-12-05       Impact factor: 3.452

8.  Curative laparoscopic resection for pancreatic neoplasms: a critical analysis from a single institution.

Authors:  Laureano Fernández-Cruz; Rebeca Cosa; Laia Blanco; Sammy Levi; Miguel-Angel López-Boado; Salvador Navarro
Journal:  J Gastrointest Surg       Date:  2007-09-25       Impact factor: 3.452

9.  Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasuo Hayashidani; Yasushi Hashimoto; Hiroki Ohge; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2007-11-17       Impact factor: 3.452

10.  Clinical importance of B7-H3 expression in human pancreatic cancer.

Authors:  I Yamato; M Sho; T Nomi; T Akahori; K Shimada; K Hotta; H Kanehiro; N Konishi; H Yagita; Y Nakajima
Journal:  Br J Cancer       Date:  2009-10-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.